For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of CureVac N.V (NASDAQ: CVAC) was $3.52 for the day, down -3.56% from the previous closing price of $3.65. In other words, the price has decreased by -$3.56 from its previous closing price. On the day, 0.91 million shares were traded.
Ratios:
Our analysis of CVAC’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.97. For the most recent quarter (mrq), Quick Ratio is recorded 6.19 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on April 25, 2024, Downgraded its rating to Market Perform and sets its target price to $4 from $12 previously.
On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.
UBS Upgraded its Neutral to Buy on January 19, 2023, whereas the target price for the stock was revised from $8 to $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 07 ’25 when Myriam Mendila bought 17,839 shares for $4.93 per share.
Pierre Kemula bought 51,523 shares of CVAC for $254,219 on Jan 07 ’25. On Jan 07 ’25, another insider, Alexander Zehnder, who serves as the affiliate of the company, bought 26,104 shares for $4.93 each.
Valuation Measures:
As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.33 while its Price-to-Book (P/B) ratio in mrq is 0.98.
Stock Price History:
Over the past 52 weeks, CVAC has reached a high of $5.28, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is -1.45%, while the 200-Day Moving Average is calculated to be 6.40%.
Shares Statistics:
A total of 224.34M shares are outstanding, with a floating share count of 93.61M. Insiders hold about 58.27% of the company’s shares, while institutions hold 4.32% stake in the company.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2.0 analysts currently analyzing and rating the stock of CureVac N.V (CVAC).The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.16 and low estimates of -$0.16.
Analysts are recommending an EPS of between $1.15 and $0.74 for the fiscal current year, implying an average EPS of $0.88. EPS for the following year is -$0.5, with 4.0 analysts recommending between -$0.47 and -$0.52.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for CVAC’s current fiscal year. The highest revenue estimate was $543.1M, while the lowest revenue estimate was $520.7M, resulting in an average revenue estimate of $530.38M. In the same quarter a year ago, actual revenue was $53.8M
